Hp Halden Pharma As

What Hp Halden Pharma As does

HP Halden Pharma AS, operating as Halden Pharma, is a Norwegian contract development and manufacturing organization (CDMO) specializing in sterile and non-sterile pharmaceutical liquids. Founded in 1977 by Baxter Travenol and now owned by Germany's Prange Pharma following a 2024 acquisition, the company operates from a 77,000 m² site in Halden, Norway, employing approximately 700 staff representing 48 nationalities. It serves global pharmaceutical companies and hospital pharmacies across more than 75 countries, with 95% of its output exported. Revenue is generated through multi-year, quote-based contract manufacturing arrangements.

The company operates an integrated manufacturing platform built around five core technology areas. IV bag production uses PLÜMAT-based Large Volume Parenteral lines with pre-formed bags supporting volumes from 50 ml to 5,000 ml and batch sizes up to 15,000 L, capable of producing over 50 million units per year. Blow-Fill-Seal (BFS) technology forms, fills, and seals containers in a single automated process for ampoules (10–30 ml) and vials (up to 100 ml) with batch sizes up to 5,000 L. Aseptic compounding uses isolator technology to produce TPN, epidural, and IV infusion preparations for hospitals. ATEX-compliant systems handle alcohol-rich and flammable non-sterile liquids and gels up to 5,300 L batches. Supporting the manufacturing platforms is an 18,000-pallet GDP-compliant warehouse with 1,250 freezer positions at -20°C and global temperature-controlled distribution.

Halden Pharma's go-to-market is enterprise B2B, with dedicated project managers serving as single point of contact and a Director of Business Development (Nina Gabrielsen) leading sales outreach. The business is qualified by extensive regulatory certifications including EU-GMP, FDA, ANVISA, EAEU, ISO 9001, and ISO 13485, plus approvals in major Asian markets, enabling access to global pharma customers. Pricing is project-specific and negotiated based on product specifications, batch sizes, and regulatory requirements rather than published rate cards. The company is led by CEO Ian Cooper and Managing Director Sebastian Heckerodt, with Chairman Otto Prange representing the Prange family ownership.

Name

Hp Halden Pharma As

Legal name

HP Halden Pharma AS

Website

https://halden-pharma.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

101–250 employees

Short description

HP Halden Pharma AS is a Norwegian CDMO specializing in contract manufacturing of sterile and non-sterile pharmaceutical liquids, producing IV bags, BFS ampoules and vials, aseptic compounds, and non-sterile liquids for global pharmaceutical companies and hospitals across 75+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Sterile pharmaceutical manufacturing
• Contract development manufacturing
• Blow-Fill-Seal technology
• IV bag production
• Aseptic compounding services

Headquarters

HQ city

Halden

HQ country

Norway

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Contract Manufacturing Services: CDMO business model providing contract development and manufacturing services for sterile and non-sterile pharmaceuticals. Revenue generated from manufacturing fees, technology transfer services, analytical services, and regulatory support. Services span from incoming materials to finished released batches.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

HP Halden Pharma AS is a Contract Development and Manufacturing Organization (CDMO) providing specialized contract manufacturing services for sterile and non-sterile pharmaceutical liquids. Its core capabilities include large-volume parenteral IV bag manufacturing using PLÜMAT technology, Blow-Fill-Seal (BFS) ampoules and vials, aseptic compounding for hospital pharmacies, ATEX-compliant non-sterile liquids and gels production, and GDP-compliant warehousing with global distribution.

Product overview

Halden Pharma is a leading CDMO (Contract Development and Manufacturing Organization) offering specialized sterile and non-sterile pharmaceutical manufacturing services. The company operates a single integrated platform comprising five core manufacturing technologies: IV Bags (LVP using PLÜMAT technology for over 50 million units annually), BFS Ampoules & Vials (SVP using Blow-Fill-Seal technology), Non-Sterile Liquids & Gels (ATEX-compliant disinfectant production), Compounding Services (aseptic manufacturing with isolator technology for hospitals), and Warehouse & Distribution (GDP-compliant logistics with 18,000 pallet capacity). These manufacturing platforms are supported by comprehensive services including Technology Transfer & Scale-Up, Testing & Quality Control, and Project Management. The company specializes in sterile liquids and serves global pharmaceutical customers from its GMP-certified facility in Norway.

Differentiator

Problem solved

Functional benefit

Products and services

• IV Bags (Large Volume Parenteral) Sterile IV bag contract manufacturing platform using PLÜMAT technology with pre-formed bags and semi-automated operation. Handles volumes from 50 ml to 5,000 ml with batch size up to 15,000 L and annual capacity exceeding 50 million units. Supports PP, PVC, and multilayer laminate foil materials with oxygen and light barrier overwraps. Serves global pharmaceutical companies.
• BFS Ampoules & Vials Small Volume Parenteral (SVP) contract manufacturing using advanced Blow-Fill-Seal technology that forms, fills, and seals containers in a single automated process minimizing human intervention. Produces BFS ampoules 10-30 ml and BFS vials up to 100 ml with batch size up to 5,000 L. Includes terminal sterilization, blistering, and packaging capabilities.
• Non-Sterile Liquids & Gels Contract manufacturing platform for non-sterile liquids and gels including disinfectants, using ATEX-compliant systems that safely handle alcohol-rich and highly flammable formulations. Batch size up to 5,300 L with bottle filling from 125 ml to 1,000 ml, including in-house bottle extrusion capabilities for rapid packaging adaptation.
• Aseptic Compounding Services Aseptic manufacturing and preparation of medicines for hospitals and healthcare providers using isolator technology and quality-assured processes. Portfolio includes standardized hospital products for pain management and IV therapy, plus customer-specific formulations such as Total Parenteral Nutrition (TPN), epidural, and IV infusion preparations.
• Warehouse & Distribution GDP-compliant warehouse and global distribution services with 18,000 pallet capacity in fully controlled environment, including freezer storage at -20°C with 1,250 pallet positions. Provides global distribution via road, air, and sea with temperature-controlled transport (20-25°C) door-to-door. Logistics operation covering 1,800 TEU worldwide and 50,000 Euro pallets annually.
• Technology Transfer & Scale-Up Services Support services for transfer of pharmaceutical products and processes from laboratory and pilot scale to commercial production, including analytical method transfer and validation, process validation, stability testing and storage, and regulatory documentation support.
• Testing & Quality Control Services Expert analytical and quality control support including manufacturing and testing of stability batches, optimization of formulations and analytical methods, quality control, sterility testing, regulatory services, and market release support for pharmaceutical customers.
• Business Development & Project Management Partnership service providing dedicated project managers as single points of contact with structured planning, strategic execution, and full regulatory compliance throughout the project lifecycle. Sales outreach managed through the Director of Business Development for long-term pharmaceutical partnerships.

Quantifiable outcome

• 100+ million units manufactured and distributed annually to 75+ countries
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Prange PharmacoreStrategic or Co-development PartnerParent company and strategic partner. Prange Pharma acquired Halden Pharma in 2024, integrating it into their international pharmaceutical group. As part of Prange Pharma, Halden Pharma benefits from long-term strategic backing and alignment with group-wide pharmaceutical manufacturing objectives. The partnership provides stability and resources for continued investment in sterile manufacturing capabilities.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Recipharm: Recipharm is a Swedish-headquartered CDMO offering sterile fill-finish, lyophilization and parenteral manufacturing across multiple European sites. Highly comparable business model, geographic footprint, and customer base to Halden's B2B CDMO offering.
• Alcami Corporation: Alcami is a US-headquartered CDMO offering sterile fill-finish, lyophilization and analytical services for injectable drug products. Directly comparable business model and customer base focused on parenteral manufacturing.
• Fareva: Fareva is a French-headquartered CDMO with sterile injectable (liquid and lyophilized) and non-sterile liquid capacity. Comparable contract development and manufacturing services model serving multinational pharma customers.
• Aenova Group: Aenova is a German CDMO providing sterile and non-sterile liquid and semi-solid manufacturing, including aseptic processing and BFS capabilities. Comparable scale, technology stack and customer profile to Halden's Northern European operations.
• Vetter Pharma: Vetter is a leading German CDMO specializing in aseptic fill-finish of sterile injectables including vials, syringes and cartridges. Direct comparability with Halden due to shared focus on aseptic manufacturing of complex parenteral dosage forms for global pharma customers.
• Simtra BioPharma Solutions: Simtra (formerly Baxter's BioPharma Solutions) is a US-based CDMO focused on sterile injectable contract manufacturing including vials, prefilled syringes and liquid fill-finish. Compares directly to Halden as a pure-play sterile parenteral CDMO serving global pharma.

Broad incumbents

• Lonza Group: Lonza is a Swiss-headquartered global CDMO offering sterile fill-finish among many other services. Comparable in aseptic manufacturing of parenterals but operates at much larger scale with broader modality coverage.
• Catalent: Catalent is a large global CDMO offering sterile fill-finish, biologics, softgel and inhalation capabilities. Overlaps with Halden on sterile injectable contract manufacturing but operates at much larger scale across broader modalities and geographies.
• Thermo Fisher Scientific (CDM Services): Thermo Fisher's CDMO services span sterile fill-finish, viral vectors and biologics. Comparable in sterile liquid manufacturing for pharma but as part of a much broader life sciences services portfolio.

Emerging players

• Bachem: Bachem is a Swiss CDMO specializing in peptide and oligonucleotide APIs with aseptic fill-finish. Partially comparable to Halden as a European sterile manufacturing CDMO serving global pharma, though with a distinct modality focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/halden-pharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hp Halden Pharma As